AstraZeneca's Evinova partners with Astellas and BMS to speed up clinical trials using its AI platform.
This collaboration signals a major industry shift towards AI-driven clinical development.
Evinova, an AstraZeneca business, partners with Astellas and Bristol Myers Squibb to accelerate clinical trials using its AI platform, leveraging shared data for AI-powered insights.
Evinova, AstraZeneca's health-tech business, announced strategic collaborations with Astellas and Bristol Myers Squibb to accelerate global clinical development using its AI-native platform. By sharing operational data, the partners will enable the platform to provide benchmarks and smarter recommendations. This aims to speed up clinical trials, reduce costs, and improve patient outcomes by moving from manual, fragmented processes to intelligent, AI-first workflows.
This collaboration signals a major industry shift towards AI-driven clinical development. By pooling data and leveraging AI, AstraZeneca and its partners can significantly shorten drug development timelines, reduce failure rates, and gain a competitive edge in bringing new therapies to market faster.
Where this signal fits in the broader landscape.
AstraZeneca's Datopotamab Deruxtecan Granted Fast Track Designation in US for Metastatic Lung Cancer
AstraZeneca Partners with Jacobio to Co-Develop and Commercialize SHP2 Inhibitors for Cancer Treatment
AstraZeneca's Enhertu Granted US Priority Review for HER2-Positive Early Breast Cancer Post-Neoadjuvant Treatment
Health Canada approves Koselugo for adults with neurofibromatosis type 1
https://www.astrazeneca.com/media-centre/press-releases/2026/evinova-announces-strategic-collaborations-with-astellas-and-astrazeneca-to-scale-digital-health-solutions.html
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
Sign In